Study on the Mechanism of Ruanjian Sanjie Capsules(软坚散结胶囊)Inducing Renal Cancer Cell Apoptosis by Blocking NOTCH Signal Pathway

Objective:To investigate the molecular mechanism of Ruanjian Sanjie Capsules(软坚散结胶囊)through regulating NOTCH signaling pathway to promote human clear cell renal cell carcinoma 7860 cell apoptosis.Methods:A laser confocal microscope was used to observe the nuclear displacement of apoptosis-related proteins,and the expression of Notch1,NICD,Bcl-2,and Bax was detected by Western blotting(WB).Results:Laser confocal microscopy showed that the immunofluorescence intensity of Bcl-2 protein gradually decreased with the increase of Ruanjian Sanjie Capsules(软坚散结胶囊)drug-containing serum concentration,and the fluorescence intensity of Bax protein gradually increased with the increase of dose concentration,and it entered the nucleus to varying degrees;WB detection showed that Bcl-2,Notch1,and NICD protein expression levels were inversely correlated with the drugcontaining serum dose concentration,that is,protein expression decreased with the increase of drugcontaining serum concentration,while Bax protein expression increased gradually with the increase of serum concentration.Afte 7860 cells knock out Notch1,the expression of related proteins was consistent with the expression trend of the drug-containing serum group.Conclusion:Ruanjian Sanjie Capsule's(软坚散结胶囊)low,medium and high dose concentration of drug-containing serum can promote 7860 cell apoptosis,and it is concentration-dependent.The molecular mechanism of apoptosis is directly related with Ruanjian Sanjie Capsule(软坚散结胶囊)blocking Notch signaling pathway activation.

软坚散结胶囊含药血清调控VEGF-ERK信号通路诱导胃癌细胞凋亡机制研究

目的研究VEGF-ERK信号通路在软坚散结胶囊含药血清诱导胃癌SGC7901细胞凋亡过程中的变化,探讨软坚散结胶囊含药血清调控胃癌细胞凋亡的机制。方法制备软坚散结胶囊含药血清;激光共聚焦显微镜观察软坚散结胶囊含药血清处理后胃癌SGC7901细胞形态变化;流式细胞仪检测软坚散结胶囊含药血清处理后胃癌SGC7901细胞凋亡率;Western Blot检测软坚散结胶囊含药血清对人胃癌SGC7901细胞ERK、P-ERK及VEGF蛋白表达影响。结果软坚散结胶囊含药血清处理细胞后,激光共聚焦显微镜下见:阴性对照组以正常活性细胞为主,Annexin V和PI均为低染,细胞膜完整,细胞形态正常;低剂量组可见Annexin V高染、PI低染,细胞膜呈绿色荧光,细胞核着色浅或不着色;中剂量组可见Annexin V高染、PI低染,细胞膜呈绿色荧光,细胞核呈桔红色荧光;高剂量组PI高染,细胞核呈红色荧光,出现部分细胞的细胞膜破裂、细胞核呈大小不等形态不规则的碎片状,为典型的细胞凋亡形态特征。流式细胞仪检测经阴性对照组及低中高剂量组含药血清处理的SGC7901细胞后,各组细胞凋亡率分别为:(6.053±0.223)%、(9.117±1.583)%、(23.663±3.428)%、(37.707±1.328)%,细胞凋亡率随软坚散结胶囊含药血清剂量的增加而升高。Western Blot检测发现SGC7901细胞中VEGF蛋白水平随含药血清剂量的增加而降低(P<0.05);ERK蛋白表达无明显变化(P>0.05),P-ERK(ERK磷酸化)蛋白水平随含药血清剂量增加而降低(P<0.05)。结论软坚散结胶囊含药血清能诱导人胃癌SGC7901细胞凋亡;其作用机制可能是通过抑制VEGF蛋白表达,调控ERK信号通路,抑制ERK磷酸化(p-ERK)表达进而促进胃癌细胞凋亡。

软坚散结胶囊含药血清诱导人肾透明细胞癌7860细胞凋亡

目的:研究软坚散结胶囊对人肾透明细胞癌7860细胞系抑制和诱导凋亡的作用。方法:分别采用CCK-8检测细胞的生长抑制率,流式细胞仪、激光共聚焦显微镜观察软坚散结含药血清处理7860细胞后细胞凋亡和细胞周期阻滞的发生。结果:软坚散结胶囊低、中、高剂量含药血清均能抑制7860细胞增殖(P<0.05),其抑制率与作用时间及血清含药浓度相关。中、高剂量含药血清处理7860细胞48h后凋亡率显著高于对照组(P<0.05),同时低、中、高剂量含药血清处理7860细胞48 h后,G0/G1期细胞明显较对照组增加(P<0.01),提示软坚散结胶囊可促进细胞凋亡,并且将细胞生长周期阻滞于G0/G1期。激光共聚焦显微镜下可见经染色的凋亡细胞增多且细胞出现凋亡形态学改变。结论:软坚散结胶囊对人肾透明细胞癌7860细胞有抑制作用,机制可能与抑制细胞生长、阻滞细胞生长周期及诱导细胞凋亡有关。

名医验方软坚散结胶囊治疗难治性肾病临床研究

难治性肾病综合征（RNS）不是一个独立性疾病,而是疾病发展过程中肾小球滤过膜不同程度损伤,通透性的改变所形成的一组临床症候群,采用西医治疗预后较差,近年来,我们使用吴康衡教授验方软坚散结胶囊配合西医常规治疗30例RNS患者,与纯西医治疗的对照组30例相比较取得满意的疗效.本研究旨在发挥中医药优势,通过验方不断优化,寻找解决难治性肾病突破点.

软坚散结胶囊联合海扶治疗子宫肌瘤的疗效评价

目的评价软坚散结胶囊联合海扶治疗子宫肌瘤的临床疗效。方法将80例子宫肌瘤患者随机分为研究组与对照组,各40例。研究组给予软坚散结胶囊联合海扶治疗,对照组给予海扶治疗。于海扶术前1天、术后1天、1个月、3个月行MRI检查,分析肌瘤的体积消融率、能效因子、体积缩小率、并发症,评价两组疗效。结果海扶治疗体积消融率、能效因子无统计学差异(P>0.05);研究组海扶术后1个月、3个月的体积缩小率高于对照组,且并发症减少,差异有统计学意义(P<0.05)。结论软坚散结胶囊联合海扶治疗子宫肌瘤明显促进肌瘤坏死组织的吸收,减少相关并发症。

软坚散结胶囊对40例腹膜透析患者腹膜硬化的改善

目的:探讨软坚散结胶囊对腹膜透析患者腹膜硬化的改善效果。方法:选取2016年01月—2020年01月间我科诊治的80例腹膜透析发生腹膜硬化患者,随机分为对照组和观察组各40例。对照组施以常规泼尼松治疗0.5~1.0 mg/kg,连续使用2~4周,期间剂量逐渐降低,第2周为0.25~0.5 mg/kg,观察组采用软坚散结胶囊每次4粒,3次/d治疗,观察对比两组临床治疗效果及治疗后症状的改善情况。结果:观察组临床总有效率87.5%明显高于对照组55%,差异有统计学意义(P<0.05);两组治疗前恶心、腹胀、便秘各症状发生情况差异无统计学意义(P>0.05),观察组治疗后恶心、腹胀、便秘各症状发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:软坚散结胶囊可缓解腹膜透析患者腹膜硬化的临床症状,有利于患者康复,值得临床推广应用。

Efficacy and Safety of Longshengzhi Capsules(龙生蛭胶囊)in Treatment of Cerebral Infarction:Systematic Review and Meta-analysis

Objective:To systematically evaluate the efficacy and safety of Longshengzhi Capsules(龙生蛭胶囊)in the treatment of cerebral infarction.Materials and methods:A randomized controlled trial of Longshengzhi Capsules(龙生蛭胶囊)for cerebral infarction was screened out by searching CNKI,Wanfang Data,VIP,Sino Med,Cochrane Library,Pub Med,Embase,Web of Science in a systematic way and was based on Handbook 5.1 evaluation criteria and tools and Rev Man 5.3 software for Meta-analysis of the final inclusion of the study.Results:A total of 12 studies were included,including 9 meta-analysis of studies and 3 other studies,with a total sample size of 1446 cases,including 746 cases in the experimental group and 700 cases in the control group.The results of Meta-analysis showed that the Chinese Stroke Chinical Neurological Deficit Scales Score(CSS)of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment alone(MD=–6.98,95%CI[–7.41,–6.55],P<0.00001).The National Institues of Health Sroke Scales(NIHSS)score of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment alone(MD=–1.49,95%CI[–1.78,–1.20],P<0.00001);The quality of life score of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment(MD=6.65,95%CI[3.97,9.33],P<0.00001).Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment in treating cerebral infarction was better than conventional treatment in Homocysteine(Hcy)(MD=–2.44,95%CI[–2.89,–1.99],P<0.00001).There was no significant difference in the incidence of adverse reactions between Longshengzhi Capsules(龙生蛭胶囊)and conventional treatment for cerebral infarction(RR=0.58,95%CI[0.31,1.06],P=0.08).The main adverse reactions were skin rash,gastrointestinal reaction,headache,dizziness,abdominal pain,irritability,chills,urticaria,blood pressure reduction,dyspnea,vomiting,fever and urinary tract infection,which did not affect the treatment.Due to the small sample size,a large sample is needed for further verification.Conclusion:Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction reduced CSS and NIHSS scores,improved quality of life scores,and reduced Hcy,without serious adverse reactions,and the incidence of adverse reactions was similar to that of conventional treatment.However,the quality of the study is not high,and it is necessary to improve the level of evidence quality by using clinical trial schemes with large samples,rigorous design and compliance with international standards.

活血化瘀软坚散结法对子宫内膜异位症细胞免疫和体液免疫功能影响的实验研究

[目的]探讨妇痛宁颗粒剂治疗治疗子宫内膜异位症(EMS)的免疫学机制。[方法]采用手术移植法制备大鼠子宫内膜异位症模型。实验共分6组 ,实验结束检测各组大鼠外周血T细胞亚群、血清免疫球蛋白IgA、IgG、IgM、IgE和补体C3 改变。[结果]模型对照组与空白对照组比较CD3、CD4、CD8 有明显变化 ,各项结果均P<0.01。除丹那唑对CD4、妇痛宁低剂量组对CD8,其余各组治疗作用明显 ,疗后与空白对照组比较均P>0.05。模型对照组血中免疫球蛋白IgA、IgG、补体C3 较空白对照组显著上升 ,P<0.01。IgM亦上升 ,P<0.05。除妇痛宁低剂量组 ,各组疗后数值均处于正常水平 ,与空白对照组比较P>0.05。IgE在各组间无明显变化。[结论]活血化瘀、软坚散结法的代表方妇痛宁 ,对子宫内膜异位症免疫功能异常具有显著调整作用 。

Analysis of the Real-world Efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)in the Treatment of Upper Respiratory Tract Infection

Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respiratory tract infection,and provide reference for rational clinical drug use.Methods:The HIS database based on 18 large third-grade class-A hospitals was selected to match 1:1 for upper respiratory tract infection patients using and without Lianhua Qingwen Capsule(莲花清瘟胶囊)according to certain standards.The recombination of treatment outcome as"recovery"and"improvement"in the database was defined as effective treatment,"ineffectiveness","death"and"other"as ineffectivetreatment populations,and the effectiveness of treatment outcomes in the remerged 2 groups was compared by propensity score method.Results:After matching,454 cases were in both the patients treated by(experimental group)and without(control group)Lianhua Qingwen Capsule(莲花清瘟胶囊).Analysis was performed by three Logistic regression methods,all showing regression coefficients greater than 0 and statistically significant differences(P<0.05).Conclusion:Patients with upper respiratory tract infection treated by Lianhua Qingwen Capsule(莲花清瘟胶囊)are more effective than that without Lianhua Qingwen Capsule(莲花清瘟胶囊),it can improve the clinical efficacy of patients with upper respiratory tract infection。

桂枝茯苓胶囊治疗子宫肌瘤60例

目的探讨桂枝茯苓胶囊治疗子宫肌瘤的临床疗效。方法对60例子宫肌瘤患者采用口服桂枝茯苓胶囊治疗,观察不同临床分型、子宫大小、B超检测大小的治疗效果。结果桂枝茯苓胶囊对不同临床分型子宫肌瘤患者均有良好的治疗效果,对浆膜下肌瘤总有效率达90%。结论桂枝茯苓胶囊治疗子宫肌瘤疗效可靠,值得临床推广使用。

岩鹿乳康胶囊治疗乳腺囊性增生症疗效观察

乳腺囊性增生症是女性的常见病及多发病,多表现为乳房周期性疼痛,可触及乳房肿块,并可对患者睡眠、情志状态等产生较大影响[1]。岩鹿乳康胶囊具有益肾、活血、软坚散结作用,用于治疗肾阳不足、气滞血瘀所致的乳腺增生症。2013年6~12月,我们对130例乳腺囊性增生症患者采用岩鹿乳康胶囊治疗,取得良好疗效,现报告如下。

脉血康胶囊联合黄葵胶囊治疗糖尿病肾病疗效观察

目的:以软坚散结法抗肾血管纤维化,解决肾脏病难治性。方法:观察组50例糖尿病肾病患者予口服脉血康胶囊联合黄葵胶囊,对照组48例予黄葵胶囊口服。结果:观察组疗效明显优于对照组(P<0.05)。结论:脉血康胶囊联合黄葵胶囊治疗DN优于单用黄葵胶囊。

曲安奈德鼻喷雾剂联合桉柠蒎肠溶胶囊治疗分泌性中耳炎

分泌性中耳炎（secretory otitis media,SOM）主要以传导性聋及鼓室积液为主要特征的中耳炎症,儿童和成人发生率均较高,治疗方法 主要为药物和鼓膜穿刺、切开置管术等,如何尽量减少有创治疗一直是临床医师探讨的问题。本研究用曲安奈德鼻喷雾剂（triamcinolone acetonide nasal spray,TANS）喷鼻加桉柠蒎肠溶胶囊（eucalyptol,limonene and pinene enteric soft capsules,ELPESC）治疗SOM取得了较好的临床治疗效果,

克癌胶囊对肝癌组织的病理形态学影响

目的:揭示克癌胶囊抗肝癌的病理学基础。方法:通过肉眼大体、光镜、电镜观察。结果:与对照组相比,克癌胶囊组绝大多数癌组织有明显完整的包膜,癌细胞浸润至周边组织中很少。光镜下见瘤灶周围常形成较完整的反应带,反应带中有大量淋巴细胞、巨噬细胞等;淋巴细胞很大一部分属于 T 细胞。电镜下癌细胞内细胞器如线粒体等显著扩张、脂褐素明显增多,核浓缩、染色质积聚、断裂、贴向核膜,出现走向凋亡的特征。结论:说明其抗癌作用包括直接作用于癌细胞和间接增强宿主细胞免疫系统两个方面。

克癌胶囊抗肝癌作用的实验研究

目的:通过实验方法揭示软坚散结方药——克癌胶囊的抗肝癌作用。方法:分体外实验和体内实验,前者包括克隆形成法、活细胞计数法和 NAG 微量酶反应法;后者主要观察荷瘤小鼠移植瘤的生长和小鼠的存活时间。结果:体外实验表明克癌胶囊能明显抑制人肝癌细胞 BEL-7402生长,ED_(50)在克隆形成法为38.5mg/L,活细胞计数法为54.0mg/L;与5-Fu 有显著的协同作用(P<0.05)。体内实验表明剂量为1.8、3.6、7.2g·kg^(-1)·d^(-1),对 BALB/C小鼠实体瘤(HepA)的抑瘤率(%)平均分别为16.6(P>0.05)、32.4(P<0.05)、49.6(P<0.01);生命延长率(%)平均分别为109(P>0.05)、135(P<0.05)、159(P<0.01),剂量与效应呈直线相关;剂量为3.6、7.2g·kg^(-)1·d^(-1),对 BALB/C 小鼠腹水癌(HepA)产生的抑制率(%)平均分别为14.2(P>0.05)、31.0(P<0.05);生命延长率(%)平均分别为110(P>0.05)、135(P<0.05)。结论:克癌胶囊有抗肝癌效果,与化疗药有协同增效作用。

甲珠软坚胶囊对慢性乙型肝炎肝纤维化指标的影响

肝硬化是一种以肝组织弥漫性纤维化、假小叶和再生结节形成为特征的慢性肝病。对于慢性乙型肝炎患者来说，肝纤维化是发展到肝硬化的必经阶段。在治疗上，中医药多采用活血化瘀、软坚散结的办法来改善症状。甲珠软坚胶囊具有益气补肾、活血软坚的功效，本研究采用甲珠软坚胶囊（本院自制药，生产批号：20120306）对慢性乙型肝炎所导致的肝纤维化患者进行抗纤维化治疗，以观察其抗纤维化的疗效。

治疗新型冠状病毒肺炎新药——莫努匹韦(molnupiravir)胶囊

2021年11月26日,世界卫生组织(WHO)召开紧急会议向全世界通报,一种令人担忧的新型冠状病毒(SARS-CoV-2)变异株正在世界各地传播,各国亟需采取应对措施。WHO定性为最高级别的、值得关切的“变异株”(variants of concern,VOC),并命名为奥密克戎(omicron),距离该变异株被发现仅2 d时间。已观察到奥密克戎在支气管中感染速度和繁殖速度比SARS-CoV-2德尔塔变异株及SARS-CoV-2原始毒株快70倍,传播力为德尔塔的3~4倍。至2022年2月24日,时隔3个月,WHO最新实时统计指出,自SARS-CoV-2暴发以来,已扩散至全球各个角落,累计确诊新型冠状病毒肺炎病例4.30亿例,死亡近97万人,95%以上是由德尔塔和奥密克戎变异株感染引起的。全球范围内已有超过100多个国家发现奥密克戎新变异毒株BA.2,其传染性比奥密克戎高30%,患者临床症状更严重,成为危害全球人类身心健康的严重传染疾病的病原体,可使多种疫苗的防疫机制失效。美国当地时间2021年11月23日,美国食品药品管理局(FDA)紧急授权,批准美国默克制药集团公司(除美国和加拿大外,均称为默沙东制药公司)与美国Ridgeback公司合作开发的第3款治疗COVID-19新药:莫努匹韦(molnupiravir)胶囊上市,商品名lagevrio。根据Ⅲ期临床试验研究的中期分析,莫努匹韦胶囊治疗SARS-CoV-2轻至中度成人和≥12岁,体质量≥40 kg的儿科患者,及具有较高重症风险的住院人群,推荐剂量为每12小时口服莫努匹韦胶囊800 mg(4粒),连续服用5 d。可使住院率或死亡风险率减低约50%。该文对莫努匹韦(商品名:lagevrio)胶囊的非临床和临床药理毒理学、临床研究、不良反应、适应证、剂量与用法、用药注意事项及知识产权状态和国内外研究进展等进行介绍。

岩鹿乳康胶囊的国内临床研究进展

岩鹿乳康胶囊是由岩陀、鹿衔草、鹿角霜组成的一种中药复方制剂,具有益肾活血,软坚散结等功效,其独特的益肾调理冲任作用机理,使其在治疗乳腺增生上表现出色,并在临床上得到广泛应用。近年来对其药理研究和临床研究逐渐增多,开始应用于月经不调、子宫肌瘤等妇科疾病。